Denali Advisors LLC Invests $481,000 in DaVita Inc. $DVA

Denali Advisors LLC bought a new position in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,237 shares of the company’s stock, valued at approximately $481,000.

Several other hedge funds have also added to or reduced their stakes in DVA. Ethic Inc. boosted its position in DaVita by 9.2% during the fourth quarter. Ethic Inc. now owns 2,723 shares of the company’s stock worth $309,000 after purchasing an additional 229 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of DaVita by 62.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 3,313 shares of the company’s stock valued at $376,000 after purchasing an additional 1,269 shares during the period. Acorn Financial Advisory Services Inc. ADV lifted its stake in shares of DaVita by 10.5% during the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 2,230 shares of the company’s stock worth $253,000 after buying an additional 212 shares during the last quarter. Intact Investment Management Inc. acquired a new position in DaVita in the 4th quarter valued at about $80,000. Finally, PFA Pension Forsikringsaktieselskab bought a new position in DaVita in the 4th quarter valued at about $1,762,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 1.1%

DVA stock opened at $198.39 on Friday. The company’s 50-day moving average price is $153.03 and its two-hundred day moving average price is $132.70. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $199.27. The firm has a market cap of $12.74 billion, a P/E ratio of 18.40, a P/E/G ratio of 0.65 and a beta of 0.84.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the business posted $2.00 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 15.07 EPS for the current year.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported Q1 results that topped expectations, with adjusted EPS of $2.87 versus consensus near $2.33 and revenue of $3.42 billion above estimates. The company also lifted its 2026 EPS guidance, reinforcing confidence in the earnings outlook. DaVita (DVA) Is Up 27.6% After Boosting 2026 EPS Guidance On Strong Q1 Results
• Positive Sentiment: UBS raised its price target on DaVita to $235 from $190 and kept a Buy rating, signaling further upside potential after the post-earnings rally. UBS Group Issues Positive Forecast for DaVita (NYSE:DVA) Stock Price
• Positive Sentiment: Multiple Zacks articles highlighted DaVita as a Strong Buy value stock and pointed to improving earnings estimate revisions, which can attract momentum and value investors. Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
• Positive Sentiment: Seeking Alpha said DaVita was upgraded to Buy after strong Q1 results, improved volumes, and a favorable valuation profile, supporting the case that the stock can continue to outperform. DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
• Neutral Sentiment: DaVita also announced participation in the BofA Securities 2026 Health Care Conference, which may keep the company in front of investors but is not a direct operating catalyst. DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DVA shares. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and upped their target price for the company from $126.00 to $220.00 in a research report on Wednesday. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. UBS Group upped their price target on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Finally, Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DaVita currently has a consensus rating of “Hold” and an average price target of $187.83.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.